Article

Investigational Drug Effective in Treating Resistant GIST, Colorectal Cancer

Author(s):

Elizabeth Whittington

Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies for GIST and metastatic colorectal cancer.

Patients with GIST, a rare gastrointestinal sarcoma, benefited from major advancements in chronic myelogenous leukemia when Gleevec (imatinib) revolutionized therapy for both cancers a decade ago. Now, an experimental drug in metastatic colorectal cancer may have the same effect. Regorafenib, which targets two cancer cell pathways, extended survival in both cancers in two separate studies.

In the GIST study, progression-free survival was extended from less than one month on placebo to 4.8 months on regorafenib. Patients in the placebo group whose cancers progressed were allowed to receive regorafenib. Because patients were allowed to cross over from the placebo group to regorafenib, the trial did not produce a statistically significant overall survival difference; however, researchers noted a trend for longer survival with regorafenib.

In the CORRECT trial, patients with colorectal cancer who received regorafenib also saw an improvement in median overall survival (6.4 months versus 5 months).

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Unlike most GI cancers, GIST starts in supportive stromal tissue, not surface cells, and is classified as a sarcoma, says Dr. Weijing Sun.
Image of man with text.
Dr. Breelyn Wilky urged newly diagnosed GIST patients to seek support from peers and advocacy groups, and to consult experts, even if care stays local.
Dr. Breelyn Wilky explains how vague symptoms and testing challenges delay GIST diagnoses
Dr. Breelyn Wilky stresses the importance of expert guidance and second opinions for patients with GIST, as treatment options continue to evolve rapidly.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Related Content
Imgae of dr. with text.
July 31st 2025

Coping With a Rare Cancer Diagnosis, Like GIST

Ryan Scott
Dr. Breelyn Wilky discusses challenges that patients with GIST face and shares advice with those who feel overwhelmed by the rarity of their condition.
Image of doctor with text.
July 31st 2025

What Patients With GIST Should Know About Their Disease

Ryan Scott
Dr. Breelyn Wilky discusses some of the most recent advancements in GIST treatment, as well as touched on the role of personalized therapy.
Image of intestines.
July 31st 2025

HT-KIT Shows Activity in Rare KIT-Driven Cancers, Preclinical Data Finds

Ryan Scott
Preclinical data has showing compelling findings for HT-KIT among patients with rare and aggressive KIT-driven cancers, including GIST and some leukemias.
A new endoscopic tunneling method allowed a patient to have a GIST removed without surgery: © stock.adobe.com.
July 31st 2025

Endoscopic Procedure Removes GIST Without Surgery

Spencer Feldman
A new endoscopic tunneling method, STER, allowed a patient to have a GIST removed without surgery, allowing quicker recovery and fewer complications.
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST: © stock.adobe.com.
July 31st 2025

First Patient Dosed in Trial of Ziftomenib for Advanced GIST

Spencer Feldman
A phase 1 trial has initiated and is investigating treatment with ziftomenib plus Gleevec in advanced GIST following progression on Gleevec.
SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy: © stock.adobe.com.
July 31st 2025

SIRT With 90Y Resin Microspheres Provides Benefit in GIST Liver Metastases

Spencer Feldman
SIRT with 90Y resin microspheres led to durable disease control in patients with gastrointestinal stromal tumor liver metastases resistant to TKI therapy.